KZR VS CASI Stock Comparison

Performance

KZR
10/100

KZR returned -90.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CASI
100/100

CASI returned 131.96% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

KZR
94/100

4 analysts offer 12-month price targets for KZR. Together, they have an average target of 17.5, the most optimistic target put KZR at 21 within 12-months and the most pessimistic has KZR at 14.

CASI
75/100

2 analysts offer 12-month price targets for CASI. Together, they have an average target of 12, the most optimistic target put CASI at 12 within 12-months and the most pessimistic has CASI at 12.

Sentiment

KZR
71/100

KZR had a bullish sentiment score of 71.02% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.88 comments, and 0.62 likes per day.

CASI

"Sentiment" not found for CASI

Technicals

KZR
29/100

KZR receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

CASI
93/100

CASI receives a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.

Earnings

KZR
10/100

KZR has missed earnings 6 times in the last 20 quarters.

CASI
10/100

CASI has missed earnings 9 times in the last 20 quarters.

Profit

KZR
10/100

Out of the last 20 quarters, KZR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CASI
10/100

Out of the last 20 quarters, CASI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

KZR
41/100

KZR has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

CASI
60/100

CASI has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Kezar Life Sciences, Inc. Common Stock Summary

Nasdaq / KZR

Healthcare

Biotechnology

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

CASI Pharmaceuticals, Inc. Ordinary Shares Summary

Nasdaq / CASI

Healthcare

Biotechnology

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Power up your portfolio